At Creyon, we are redefining what’s possible in RNA drug design. Creyon is an AI-driven drug development company creating tissue-specific, RNA-targeted nucleic acid therapies that are designed to be safer, more effective, and easier for patients to stay on. Our focus is on conditions where current RNA therapies face barriers to delivery and tolerability, including neuromuscular, central nervous system (CNS), and immunology disorders. Our mission is to unlock the full therapeutic potential of RNA medicines through intelligent design, precise delivery, and a deep understanding of tissue biology enabling better outcomes and improved quality of life for patients. Our vision is that the next generation of RNA medicines will be tissue-aware, computationally designed, and patient-centered, and we plan to lead that transformation bringing precision, predictability, and accessibility to RNA drug development.
| Website | https://www.creyonbio.com |
| Revenue | $5.5 million |
| Employees | 42 (42 on RocketReach) |
| Founded | 2019 |
| Industry | Pharmaceutical Manufacturing, Biotechnology |
| Keywords | Oligonucleotide Therapeutics, Drug Development, Pharmaceutical Innovation, Biotechnology, Precision Medicine, Synthetic Biology, Dna Therapeutics, Rna Therapeutics, Gene Therapy, Nucleic Acid Therapeutics, Oligonucleotide Synthesis, Biopharma, Drug Discovery, Pharmaceutical Research, Molecular Medicine, Oncology, Rare Diseases, Biotechnology Research |
| Competitors | Amgen, Integrated DNA Technologies, Elekta, Twist Bioscience, Benchling, CureVac, Zymergen, Inc., Synthego Corporation, Codexis, Inc., Synthorx Inc +40 more (view full list) |
Looking for a particular Creyon Bio employee's phone or email?
The Creyon Bio annual revenue was $5.5 million in 2026.
Serge Messerlian is the Chairman and CEO of Creyon Bio.
42 people are employed at Creyon Bio.
Creyon Bio is based in San Diego, California.